(I) encourage technological innovation. Continue to increase investment in pharmaceutical R & D, with China's independent intellectual property rights of the development of new drugs, in scientific research projects, funding subsidies, approval of new drugs, access to the medical insurance catalog and technological transformation investment support. Encourage basic research and development ****, critical and cutting-edge major pharmaceutical R & D topics. Support enterprises to strengthen the construction of technology centers, through the production, learning and research integration of technological resources, and promote enterprises to become the main body of technological innovation.
(ii) strengthen technological transformation. The development of the pharmaceutical industry investment guide for technological transformation, technological transformation as a means to promote structural adjustment. Support in line with the direction of structural adjustment, the pharmaceutical industry upgrading has a significant role in driving the technological transformation of enterprises, focusing on supporting the industrialization of innovative drugs, basic drugs on the level of upgrading the quality assurance system of drug production, modernization of traditional Chinese medicine, medical equipment localization.
(3) play the role of drug price leverage. Improve the drug price policy, adhere to the basic principles of encouraging innovation and promoting enterprises to improve product quality, according to the degree of innovation, the cost and profit differential control, especially for products with independent intellectual property rights, in the price approval process to give a separate price-setting policy.
(4) Improvement of centralized procurement and clinical use policies. It will study and formulate more scientific and reasonable standards and methods for evaluating bids for centralized procurement, rationally classify drug categories, effectively implement the principle of "giving priority to quality and reasonable prices", and establish an open and transparent social supervision mechanism to realize fair competition and elimination of the fittest. Deepen the reform of public hospitals, promote the separation of medicine, improve the basic medical insurance payment method, standardize clinical diagnosis and treatment behavior, promote the rational use of medicines, and create a good external environment for product restructuring.
(E) to play a role in promoting drug regulation. Improve the technical threshold for drug review and approval, and strictly control the number of new pharmaceutical enterprises. The implementation of the "new drug registration special approval procedures for the management of regulations", "drug technology transfer registration regulations" and "national drug quality standards to improve the action plan", to encourage and guide enterprises to speed up technological innovation, improve product quality, the implementation of the combination of strong and strong, and promote the optimization and upgrading of the structure of the pharmaceutical industry.
(F) improve the merger and reorganization of enterprises to support policies. Conscientiously implement the policy measures related to the merger and reorganization of enterprises, properly resolve the surplus staff resettlement, transfer of business assets, debt approval and disposal, distribution of financial and tax benefits, etc., the large-scale enterprises across the provinces (autonomous regions and municipalities) reorganization of the reorganization of the expansion of the project to be given priority to be approved in the issuance of shares, corporate bonds, medium-term notes, as well as bank loans to give support.
(7) Stopping duplication of construction and eliminating backward products and processes. Revise and improve the "Industrial Structure Adjustment Catalog" and the "Industrial Guidance Catalog for Foreign Investment", formulate access conditions for important products, and guide the direction of enterprise investment. Standardize the commissioned production of drugs, revitalize the stock of assets, guide and supervise enterprises to eliminate backward production processes and low quality standards in the same variety of products in a timely manner, and promote structural adjustment.
(viii) promote the industrialization of Chinese herbal medicine production. Encourage enterprises to establish raw material bases of Chinese herbal medicines, play its role in driving the production of Chinese herbal medicines, and promote the industrialization of Chinese herbal medicines production and the implementation of the "Chinese herbal medicines production quality management standard" (GAP). Advanced cultivation techniques should be applied, and large-scale cultivation should be promoted to ensure the quality and supply of Chinese herbal medicines. Artificial selection and breeding of important wild medicinal herbs species should be strengthened to stop over-excavation, biotechnology should be applied to the breeding of excellent seed sources, seedling bases and cultivation test demonstration bases should be established and improved, the home-growing of wild medicinal herbs should be promoted, and dependence on wild medicinal herbs should be reduced, so as to lay the foundation for the sustainable development of modern traditional Chinese medicine.
(IX) promote the development of pharmaceutical industry clusters. Encourage better basic conditions of the pharmaceutical industrial park to carry out in-depth work to create a national industrial demonstration base of new industrialization, in the planning and layout, technological transformation and funding arrangements, etc., the demonstration base to be the focus of guidance and support, to guide it to strengthen the integrated service system and public **** infrastructure, to attract related enterprises in the park, the formation of a number of standardized management, environmentally friendly, high degree of industrial relevance, professional and complete matching of the pharmaceutical industry cluster. The pharmaceutical industry gathering area with complete support.
(J) to strengthen the operation of monitoring and analysis. Improve the operation of the pharmaceutical industry monitoring system, closely track the implementation of the key tasks of structural adjustment, study and solve new problems, timely release of industry information, production and management of enterprises and investment decisions to provide information to guide.
(xi) play the role of industry associations. Industry associations should give full play to the role of bridge and link to guide enterprises to accelerate structural adjustment, reflect the industry situation, problems and enterprise demands, strengthen industry self-discipline, and promote the healthy and orderly development of the industry.
Ministry of Industry and Information Technology
Ministry of Health
State Food and Drug Administration
October 9, 2010